A randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age.

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.